Accumulating evidence supports the involvement of the gastrointestinal (GI) system in Alzheimer’s disease (AD), however, it is currently unknown whether GI alterations arise as a consequence of central nervous system (CNS) pathology or play a causal role in the pathogenesis of the disease. The GI mucus system is a possible mediator of GI dyshomeostasis in neurological disorders as CNS controls mucus production and secretion via the efferent arm of the brain-gut axis. The aim was to use a brain-first model of sporadic AD induced by intracerebroventricular streptozotocin (STZ-icv) to dissect the efferent (i.e. brain-to-gut) effects of isolated central neuropathology on the GI mucus system. Quantification and morphometric analysis of goblet cell mucigen granules revealed altered GI mucus secretion in the AD model possibly mediated by the insensitivity of AD goblet cells to neurally-evoked mucosal secretion confirmed by ex vivo cholinergic stimulation of isolated duodenal rings. The dysfunctional efferent control of the GI mucus secretion results in altered biochemical composition of the mucus associated with reduced glycoprotein aggregation and binding capacity in vitro . Finally, functional consequences of the reduced barrier-forming capacity of the AD mucus are demonstrated using the in vitro two-compartment caffeine diffusion interference model. Isolated central AD-like neuropathology results in the loss of efferent control of GI homeostasis via the brain-gut axis characterized by the insensitivity to neurally-evoked mucosal secretion, altered mucus constitution, and reduced barrier-forming capacity potentially increasing the susceptibility of STZ-icv rat model of AD to GI and systemic inflammation induced by intraluminal toxins, microorganisms, and drugs.
Introduction: Delays in Breast Cancer diagnosis and treatment remain common in low and middle‐income countries (LMICs), yet evidence on the effectiveness and sustainability of quality improvement (QI) initiatives in resource‐constrained cancer centers is limited. We prospectively evaluated a quality improvement (QI) initiative designed to reduce treatment delays at a national cancer center in Mexico and assessed the sustainment of its effects. Materials and Methods: We analyzed time intervals for 933 newly diagnosed breast cancer patients presenting between September 2023 and December 2024 across three phases: pre‐intervention, active intervention, and sustainment. The QI initiative was informed by a prior needs assessment and included workflow modifications, systematic monitoring and feedback on time‐to‐care metrics, and monthly multidisciplinary meetings. Outcomes included median Total Time‐to‐Treatment (TTT), Time‐to‐Diagnosis (TTD), Time‐to‐Tumor Board (TTB), and Time‐from‐Diagnosis‐to‐Treatment (TDT). Results: Median TTT decreased from 51 days at baseline to 43 days during the intervention phase ( p < 0.001) but returned to 51 days during sustainment. TTB showed consistent improvement, decreasing from 34 days at baseline to 28 days during the intervention and remained shorter during sustainment (27 days, p < 0.001 vs. baseline). TTD did not improve during active implementation but decreased during sustainment (19 days, p < 0.001). TDT did not change significantly during the intervention (26 vs. 22 days) but increased to 30 days during sustainment ( p < 0.001 vs. intervention). Monthly patient volume increased by 24.1% between the baseline and sustainment periods, coinciding with the loss of overall TTT improvement. Conclusions: This low‐cost QI initiative produced meaningful reductions in BC treatment delays and achieved sustained improvements in Time‐to‐Tumor Board. However, gains in overall treatment timeliness were not sustained as patient volume and external system pressures exceeded institutional capacity. These findings underscore both the potential and limitations of workflow‐focused QI initiatives in resource‐constrained cancer centers and underscore the importance of evaluating sustainment alongside short‐term effectiveness.
Introduction: Traditional oncology outcome measures, such as survival rates and disease progression, fail to fully capture the complex lived experiences of persons and patients with cancer, including psychological distress, financial burdens and changes in social roles. While person- and patient-centred outcomes have emerged as essential components of quality cancer care, ambiguities persist regarding their definitions and measurement methodologies in clinical trials. Methods and analysis: This scoping review aims to explore how person-centred and patient-centred outcomes are defined and measured in cancer clinical trials and to identify trends, gaps and methodological approaches for their assessment. Comprehensive searches will be conducted across PubMed, SCOPUS, Sci-Elo, EMBASE, PsycINFO and Google Scholar for grey literature sources, encompassing articles from August 2020 to August 2025. Eligible studies include primary research that reports patient- or person-centred outcomes in cancer clinical trials. Studies focusing solely on preventative care or lacking assessment of patient- or person-centred outcomes will be excluded. Studies will be independently screened and selected by two reviewers in duplicate, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews. Data extraction will also be conducted independently and in duplicate using a standardised extraction tool, with disagreements resolved through consensus to ensure consistency and accuracy. Results will be synthesised qualitatively and quantitatively, with narrative and thematic analysis used to identify trends and gaps in the literature. Ethics and dissemination: Ethical approval is not required. Results will be published in a peer-reviewed journal and presented at conferences. Trial registration number: https://doi.org/10.17605/OSF.IO/EYZPK